• Sagimet Biosciences dosed the first patient in its pivotal U.S. AURORA Phase 3 trial of oral denifanstat for moderate to severe acne.
• Planned enrollment totals approximately 800 patients aged 12 or older, including 450 adolescents aged 12 to 17.
• Topline results are expected in the second half of 2027; the trial is intended to support a potential U.S. marketing application.
• The program builds on positive Phase 3 results from Chinese license partner Ascletis.
• Ascletis’ 52-week extension results were already presented at the 2026 EADV Congress and Fall Clinical Dermatology Conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220700PRIMZONEFULLFEED9850969) on October 22, 2026, and is solely responsible for the information contained therein.